


Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3
4 **A novel approach to consecutive extraction of drugs with different properties via**
5
6 **on chip electromembrane extraction**
7
8
9

10
11
12 Yousef Abdossalami Asl^a, Yadollah Yamini^{a,*}, Shahram Seidi^b
13

14
15 ^a*Department of Chemistry, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran*

16
17 ^b*Department of Analytical Chemistry, Faculty of Chemistry, K.N. Toosi University of Technology, Tehran, Iran*
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 * Corresponding author at: Tarbiat Modares University, Department of Chemistry, P.O. Box 14115-175, Tehran, Iran.
53 Tel.: +98 21 82883417; Fax: +98 21 82883455.
54 E-mail address: yyamini@modares.ac.ir (Y. Yamini).
55
56
57
58
59
60

Abstract

In the present research, for the first time, a consecutive on chip electromembrane extraction coupled with high performance liquid chromatography was introduced for analysis of betaxolol (Bet), naltrexone (Nalt) and nalmeferene (Nalm) as model analytes with different chemical properties from biological samples. The chip consists of two polymethyl methacrylate (PMMA) parts which two microfluidic channels are craved in each part. These channels were used as a flow path for sample solution and a thin compartment for acceptor phase. A porous polypropylene sheet membrane impregnated with an organic solvent was placed between two parts of chip device in order to separate the channels. Two platinum electrodes were bent at the bottom of these channels that are connected to a power supply providing the electrical driving force for migration of ionized analytes from the sample solution through the porous sheet membrane into the acceptor phase. The new setup provides effective and reproducible extractions by using low volume of sample solution. Efficient parameters on consecutive electromembrane extraction of the model analytes were optimized by using one variable at a time method. Under the optimized conditions, the new setup offered a good linearity in the range of 10.0–500 $\mu\text{g L}^{-1}$ with coefficient of determination (R^2) higher than 0.9932. The relative standard deviation (RSD %) and LOD values were less than 6.8% based on four replicate measurements and 10.0 $\mu\text{g L}^{-1}$ for the model analytes, respectively. The preconcentration factors higher than 15.6-fold were obtained. Finally, the proposed method was successfully applied for determination and quantification of the model analytes in biological samples.

Keywords: Consecutive on chip extraction; Electromembrane extraction; Betaxolol; Naltrexone; Nalmeferene.

Introduction

Sample preparation has unique meaning and special importance in the field of analytical chemistry. For several decades, liquid-liquid extraction (LLE) has been employed for sample preparation prior to analysis by high performance liquid chromatography and gas chromatography¹⁻⁵. Recent developments of sample preparation are directed toward down scaling and automation of conventional extraction methods by decreasing acceptor-to-donor ratio in order to reduce organic solvent, sample solution and chemical reagents consumption⁶. Liquid phase micro extraction (LPME) is a miniaturization of the traditional LLE that performed in several modes such as single drop microextraction, dispersive liquid-liquid microextraction, porous membrane based LPME and solidification of floating organic droplet⁷⁻¹³. Electromembrane extraction (EME), as one of the LPME methods that was introduced by Pedersen-Bjergaard and coworkers in 2006¹⁴. In this method, the mass transfer is carried out through an organic solvent immobilized within the pores of a porous membrane by applying an electrical potential difference, as the driving force, between two platinum electrodes placed on both sides of the porous membrane in donor and acceptor phases. EME has numerous advantages in comparison with other liquid phase microextraction and provides more efficient, fast, very selective extractions and excellent sample cleanup¹⁵.

In addition to miniaturization of extraction techniques, downscaling of extraction devices has important role in decreasing of organic solvent, sample solution and chemical reagents consumption. Miniaturization of analytical methods and instruments for extraction researches is an area of burgeoning interest. In many cases, the reduction in size of analytical procedure or technique often translates to a reduction in analysis time and costs. Miniaturized devices integrate sample preparation, separation and detection on a single small chip¹⁶⁻¹⁸. A miniaturized and portable device is more preferable for the on-site and rapid analysis application.

1
2
3 The combination of microfluidic technologies and EME would be suitable for such
4 applications. For the first time, on chip electromembrane extraction (EME) as one type of
5 miniaturized membrane based LPME techniques was introduced by Pedersen-Bjergaard and
6 Rasmussen in 2010¹⁹. In this technique, a piece of porous membrane is used as the support for
7 water-immiscible organic solvent. Afterwards, several reports have been emerged on
8 implementation of EME as chip based devices to make more developments in this field of area²⁰⁻²³.
9

10
11
12 In all of the reported papers using chip devices, one extraction chamber has been used for
13 extraction. Therefore, analytes with different properties including hydrophilicity, polarity and
14 functional groups cannot be extracted with these devices. By considering the polarity of various
15 analytes, different supported liquid membrane (SLM) compositions are required to extract the target
16 analytes. Adding of a carrier into SLM composition has different effects on the extraction of
17 analytes. It has been demonstrated that the use of carriers in SLM composition has strong negative
18 effect on extraction of nonpolar drugs such as betaxolol (Bet)^{24, 25}. However, the presence of di-(2-
19 ethylhexyl) phosphate (DEHP) as an anionic ion pairing reagent is necessary for the extraction of
20 compounds such as naltrexone (Nalt) and nalmefene (Nalm)²⁶. Therefore, Bet could be extracted by
21 use of only pure 2-nitrophenyl octyl ether (NPOE) as the SLM, whereas for the extraction of Nalm
22 and Nalt a mixture of NPOE and DEHP is required. Consequently, the simultaneous extraction of
23 these analytes is impossible.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45
46 In the current paper, consecutive electromembrane extraction chip as a new on chip EME setup
47 was introduced for extraction and determination of Nalt, Nalm and Bet from biological samples. The
48 used analytes were selected as the model compounds with different physicochemical properties to
49 show the ability of the proposed technique for simultaneous extraction of analytes with different
50 chemical properties. In fact, the physicochemical properties of analytes are the important keys for
51
52
53
54
55
56
57
58
59
60

1
2
3 the selection of membrane organic solvents so that with selection of a specific composition of
4 membrane organic solvent selective extraction can be achieved in EME²⁴. The proposed method
5 provides the using possibility of different compositions of membrane organic solvent and thus
6 simultaneous extraction of different analytes with different chemical properties. As well known,
7 todays many combination drugs, which are a mixture of two or more drugs, are used by the patients.
8 On the other hand a patient may use several drugs, simultaneously. The proposed method can be
9 used an efficient sample preparation method because it provides the simultaneous analysis
10 possibility of all drugs by a little volume of a biological sample whereas by other techniques
11 separated samples, and consequently larger volumes of biological samples, should be used for
12 analysis of analytes with different physicochemical properties. Here, two extraction chambers were
13 employed in which anode and cathode electrodes embedded at the bottom of microfluidic extraction
14 channels, and SLMs were separately optimized for each class of analytes. As a result, the proposed
15 system offers suitable conditions for the consecutive extraction of Bet, Nalt and Nalm as model
16 analytes and can be applied for the extraction of other compounds with similar properties. Effects of
17 different variables on the extraction efficiency of the analytes were studied and optimized. After
18 optimization, the method followed by high-performance liquid chromatography–ultraviolet detection
19 (HPLC–UV) was applied for the extraction and determination of Bet, Nalt and Nalm in human urine
20 and plasma samples.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Experimental**

47 **Chemicals and reagents**

48 Betaxolol was kindly donated by Sina Darou (Tehran, Iran). Nalmefene and naltrexone were
49 obtained from Parand Darou (Tehran, Iran). Chemical structures, pK_a and $\log P$, which P is octanol-

1
2
3 water partition coefficient, of the analytes were reported in Table 1. 2-Nitrophenyloctyl ether
4 (NPOE), 2-nitrophenyl phenylether (NPPE), tris-(2-ethylhexyl) phosphate (TEHP) and di-(2-
5 ethylhexyl) phosphate (DEHP) were purchased from Fluka (Buchs, Switzerland). All of the
6 chemicals used were analytical-reagent grades. The Accurel 2E HF (R/P) polypropylene membrane
7 sheet was supplied by Membrana (Wuppertal, Germany) with the thickness of 150 μm , and pore size
8 of 0.2 μm . Ultrapure water was prepared by a Younglin 370 series aqua MAX purification
9 instrument (Kyounggi-do, Korea).

10
11
12
13
14
15
16
17
18
19
20 A stock solution containing 2.0 mg mL⁻¹ of Bet, Nalt and Nalm was prepared in methanol. All
21 standard solutions were stored at 4°C which is protected from light. Working standard solutions
22 were prepared daily by dilution of the stock solutions with ultrapure water.
23
24
25

26 27 **Real samples**

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Urine sample: To plot the calibration curves and to obtain figures of merit, a human urine
sample was collected from a 29-year-old healthy adult male volunteer. The sampling procedure was
performed according to the guidelines for research ethics. The protocol was approved by an Internal
Review Board. Moreover, written consent was obtained from volunteers prior to the experiment. The
sample was filtered through 0.45- μm pore size cellulose acetate filter from Millipore (Madrid,
Spain). The filtrate was collected in a glass vial, which was carefully cleaned with hydrochloric acid
and washed with deionized water and stored at 4°C to prevent bacterial growth and proteolysis. The
urine sample was diluted 1:4 with ultra-pure water and the pH value was adjusted to 7.00 by adding
proper amounts of hydrochloric acid (100 mM) and/or sodium hydroxide (100 mM) solutions. Then,
the urine sample was spiked with a mixed standard solution to obtain the desired concentration. One
milliliter of the sample solution was subsequently submitted to on chip EME procedure. Further
urine sample was obtained from a healthy volunteer (29-year-old).

1
2
3 Plasma sample: Frozen drug-free human plasma sample (blood group B+) was obtained from
4 the Iranian Blood Transfusion Organization (Tehran, Iran). Prior to use, the plasma sample was
5 allowed to thaw at room temperature. According to literature, trifluoroacetic acid (TFA) is a suitable
6 reagent for protein precipitation and decreasing the matrix effect of real samples such as human
7 plasma²⁷. To this end, four drops of concentrated TFA (99 w/w%) were added into 10 mL of each
8 plasma sample and centrifuged for 5 minutes at 3000 rpm, afterwards. Finally, the supernatant
9 sample solutions were transferred to a glass container and stored in 4 °C for subsequent experiments.
10 The pH of 5-fold diluted human plasma samples with ultra-pure water was adjusted at 7.0 using the
11 proper amounts of hydrochloric acid (100 mM) and/or sodium hydroxide (100 mM) solutions. Then,
12 the plasma sample was spiked with a mixed standard solution to obtain the desired concentration.
13 One milliliter of the sample solution was subsequently submitted to on chip EME procedure.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Chromatographic apparatus**

30
31 The chromatographic equipment consisted of an Agilent 1260 HPLC system, including a
32 quaternary pump, degasser, and UV-Vis detector (Waldbronn, Germany). Chromatographic data
33 were recorded and analyzed by using Chem Station for LC systems software (version B.04.03). The
34 separations were performed on an ODS-3 column (150 mm × 4.6 mm, with particle size of 5 μm)
35 from MZ-Analysentechnik (Mainz, Germany) via an isocratic elution at the flow rate of 1.0 mL
36 min⁻¹. For Bet, Nalt and Nalm, the mobile phase consisted of 10 mM phosphate buffer (pH = 8.0)
37 and acetonitrile (55:45) respectively for 15 minutes. The detector wavelength was set at 215 nm.
38
39
40
41
42
43
44
45
46
47
48

49 **Manufacture of on chip EME device**

50
51 The structure of the consecutive chip device for electromembrane extraction is shown in Fig. 1.
52 The chip consists of two polymethyl methacrylate (PMMA) parts. In each part two long channels
53 with a length of 30 mm, depth of 200 μm and width of 1.0 mm was craved. As shown in Fig. 1, the
54
55
56
57
58
59
60

1
2
3 channels, which were craved in upper part, acted as acceptor phase channels, whereas the other two
4
5 channels locating in lower part are a flow path for donor solution. Moreover, in each part of the
6
7 consecutive chip device, six individual holes (with I.D. of 0.5 mm) were drilled. The holes of “a”
8
9 and “f” were connected to inlet and outlet tubes whereas the holes of “b” and “d” were used for the
10
11 entrance of platinum electrodes. Holes of “c” and “e” were connected together to deliver extraction
12
13 solutions from one extraction chamber to the other one. In each part of the consecutive chip device,
14
15 two platinum electrodes were bent and mounted at the bottom of each channel along with its length
16
17 after passing through the holes of “b” and “d”. All channels and holes were milled using a CNC
18
19 micromilling machine model SMG-302 CNC milling from Sadrafan Gostar Industries (Tehran,
20
21 Iran). The channels of sample solution and acceptor phase were separated with two separated small
22
23 pieces of porous polypropylene sheet membrane during extraction which was impregnated with
24
25 suitable organic solvents regarding the physicochemical properties of the model analytes. The sheet
26
27 membranes were located between the two parts along with lengths of the channels and fixed using
28
29 four bolts and nuts during the extraction procedure. After each extraction step, the porous sheet
30
31 membrane was replaced with a new one. The sample solution was flowed toward inlet of the sample
32
33 channel by a syringe pump. In addition, a micro syringe was used for introducing and withdrawing
34
35 of a microliter volume of acceptor solution into the acceptor phase channel.
36
37
38
39
40
41
42

43 **Consecutive on chip EME procedure**

44
45
46 One milliliter of the sample solution containing the target analytes was filled into a Hamilton
47
48 syringe and then the syringe mounted on a syringe pump. To impregnate the organic solvent into the
49
50 pores of the sheet membrane, two 3 mm × 4 cm pieces of the porous membrane were cut and dipped
51
52 into the suitable organic solvents for 5 s and then the excess of organic solutions were gently wiped
53
54 away by using a piece of Kleenex. Then, the membranes were carefully placed between two parts of
55
56
57
58
59
60

the chip device. The upper and lower parts of the chip were fixed together using bolts and nuts. Thirty microliters of 100 mM HCl (acceptor solution) was introduced into the acceptor channel by a microsyringe. Donor phase pumped through the donor channel using a syringe pump. When the extraction was completed, the acceptor solution was collected by a microsyringe and injected into HPLC injection loop. After each extraction, the channels of sample solution and acceptor phase were washed by ultrapure water and a new porous membrane impregnated with suitable organic solvent was located and fixed between two parts of extraction chip device for subsequent experiment. Fig. 2 illustrates the extraction process, schematically.

Calculation of preconcentration factor, extraction recovery, and relative recovery

The preconcentration factor (PF) was defined as the ratio of the final analyte concentration in the acceptor phase ($C_{f,a}$) and the initial concentration of analyte ($C_{i,s}$) in the sample solution:

$$PF = \frac{C_{f,a}}{C_{i,s}} \quad (1)$$

where $C_{f,a}$ was calculated from a calibration graph obtained from direct injection of standard solutions of the analytes. The extraction recovery ($ER\%$) was defined as the percentage of the number of moles of the analyte extracted into the acceptor phase ($n_{f,a}$) respected to the number of moles originally present into the sample solution ($n_{i,s}$).

$$ER\% = \frac{n_{f,a}}{n_{i,s}} \times 100 = \frac{C_{f,a} \times V_{f,a}}{C_{i,s} \times V_{i,s}} \times 100 \quad (2)$$

$$ER\% = \left(\frac{V_{f,a}}{V_{i,s}} \right) \times PF \times 100 \quad (3)$$

where $V_{f,a}$ and $V_{i,s}$ are the volumes of the acceptor phase and sample solution, respectively. The relative recovery ($RR\%$) was calculated by the following equation:

$$RR\% = \frac{C_{\text{found}} - C_{\text{real}}}{C_{\text{added}}} \times 100 \quad (4)$$

$$\text{Error}\% = RR\% - 100 \quad (5)$$

where C_{found} , C_{real} , and C_{added} are the concentrations ($\mu\text{g L}^{-1}$) of analyte after adding a known amount of standard into the real sample, the concentration of analyte in real sample, and the concentration of a known amount of standard, which was spiked into the real sample, respectively.

Results and discussion

Selection of supported liquid membrane

Composition of the organic solvent which was used as SLM has an important role in EME. A suitable liquid membrane enhances the extraction efficiency and selectivity. Composition of membrane affects the diffusion coefficient of analyte. Furthermore, the range of applied voltage is determined by nature of SLM composition. Considering the above points, some organic solvents such as 2-nitrophenyl octyl ether (NPOE), NPOE containing 5, 10 and 15% (v/v) di-(2-ethylhexyl) phosphate (DEHP), NPOE containing 5, 10 and 15% (v/v) tris-(2-ethylhexyl) phosphate (TEHP) and NPOE containing 5% TEHP and 5% DEHP was investigated as SLM for the consecutive on chip EME. As shown in Fig. 3A, NPOE containing 10% DEHP represented higher extraction efficiency for Nalt and Nalm where suitable extraction efficiency for Bet was provided when pure NPOE was used as SLM. Thus, NPOE containing 10% DEHP and NPOE were selected as the optimum SLM compositions for the subsequent experiments.

Effect of sample solution and acceptor phase compositions

The pHs of sample solution and acceptor phase are critical parameters in extraction efficiency of consecutive on chip EME. In EME, the electrokinetic migration of the analytes across the SLM

1
2
3 into the acceptor solution is affected by ion balance which is defined as the ratio of the total ionic
4 concentration in the sample solution to that in the acceptor solution ²⁸. In EME, for basic analytes,
5 ion balance is mainly considered as the ratio of HCl concentration in sample solution to acceptor
6 phase ²⁹. Based on the previous studies on the role of ion balance, it was anticipated that decreasing
7 of ion balance leads to an increase in the flux of ions through SLM. Therefore, for a basic drug, the
8 extraction efficiency is increased by increasing the HCl concentration into the acceptor phase and its
9 decreasing into the sample solution. It can be attributed to this fact that increasing of the HCl
10 concentration into the acceptor phase not only avoids from partial deprotonation of the analyte and
11 its back-diffusion into SLM but also, accelerate the analyte release from SLM into the acceptor
12 solution. On the other hand, for extraction of the basic analyses into the acceptor phase, acidification
13 of the sample solution is performed to keep the targeted compounds in their ionized form. However,
14 there are some limitations for increasing of HCl concentration in both donor and acceptor phase. By
15 applying an electrical field in EME, cations migrate toward cathode and anions migrate toward
16 anode through the SLM. Increasing content of ions in each of donor and acceptor phase results to
17 increasing number of ions migrate through SLM at a given moment, it causes to increasing of the
18 current level, increasing of Joule heating therefore instability of SLM. Increasing of the current level
19 between electrodes increase electrolysis reactions on the surfaces of electrodes and therefore bubble
20 formation risk. Bubble formation increases uncertainties in obtained data for EME. According to the
21 previous EME works that were carried out for extraction of these model analytes ²⁴⁻²⁶, 10.0 mM and
22 100.0 mM of HCl were selected as donor and acceptor solutions, respectively.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Effect of applied voltage**

52
53
54 In EME, the electrical field, which is provided by applying an electrical potential between two
55 platinum electrodes, stimulates the transfer of analytes through the SLM into the acceptor phase.
56
57

1
2
3 Therefore, mass transfer is greatly depended on the electrical field so that it is expected that
4 extraction efficiency can be increased by increasing the applied voltage. However, at the high
5 applied voltages, several problems such as bubble formation due to electrolysis process, SLM
6 punctuation, and sparking may be occurred ²⁹. Therefore, selecting an optimum applied voltage is
7 necessary to succeed electromembrane extraction. Hence, a series of experiments with various
8 extraction voltages in the range of 0-140 V were examined to determine the most suitable voltage
9 while 10 mM HCl and 100 mM HCl was used as donor and acceptor solutions, respectively, for 30
10 min. As shown in Fig. 3B, relatively high peak areas were obtained at the voltage of 100 V.
11 Therefore, electrical potential of 100 V was applied for future experiments.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Effect of sample volume**

26
27 Sampling is one of the main problems related to the analysis of biological real samples. Except
28 urine, preparing sample with large volumes for other biological samples is difficult. The main
29 purpose for design and construction of a consecutive on chip EME was low consumption of sample
30 solution. In the current research, by considering the above reasons, 1.0 mL of sample solution was
31 selected for the subsequent experiments.
32
33
34
35
36
37
38
39

40 **Effect of sample solution flow rate and extraction time**

41
42 A syringe pump was used to pump the sample solution into the on chip EME device. The flow
43 rate of the sample solution plays an essential role in increasing the kinetics and efficiency of
44 extraction by delivering a sample solution into extraction chambers, increasing the mass transfer and
45 decreasing the thickness of the double layer around SLM ^{30, 31}. Various sample flow rates in the
46 range of 10–60 $\mu\text{L min}^{-1}$ were examined. As shown in Fig. 3C, extraction efficiency increased by
47 increasing sample flow rate from 10 to 30 $\mu\text{L min}^{-1}$, whereas a decreasing was observed by further
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 increasing of the flow rate. When the sample flow rate is increased considerably, target analysts do
4
5 not have enough time to pass through the SLM into acceptor phase. Also, perforation in the porous
6
7 membrane as well as losing of impregnated organic solvents into the pores of porous membrane
8
9 sheets were observed at high sample flow rates.
10
11

12
13 Fig. 3C also illustrates the effect of extraction time on the extraction efficiency. Extraction
14
15 time depends on the sample flow rate, inversely. Therefore, extraction time and sample flow rate was
16
17 investigated together. As can be seen, extraction time is increased by decreasing of sample flow rate.
18
19 But, stability of SLM is decreased at long extraction durations. When the sample solution is pumped
20
21 at low flow rates, accumulation of the ions around SLM is increased which leads to increasing of the
22
23 charge density of the double layer; increasing of electrokinetic migration of ions through SLM;
24
25 increasing of Joule heating and consequently instability of SLM. Therefore, $30 \mu\text{L min}^{-1}$ was
26
27 selected as the optimum sample flow rate.
28
29
30
31

32 **Method evaluation**

33
34
35 To verify the practical applicability of the proposed technique, figures of merit of the proposed
36
37 method were studied by using standard solutions of the analytes in drug-free plasma and urine
38
39 samples. Optimal conditions were applied to find out linearity, repeatability, and LODs of this
40
41 method that is summarized in Table 2. The calibration curves were linear in the range of 10.0–500
42
43 $\mu\text{g L}^{-1}$ with a coefficient of determination (R^2) more than 0.9932. The relative standard deviations
44
45 (RSD%) for extraction and determination of the model analytes were less than 6.8% based on four
46
47 replicate measurements. LODs less than $10.0 \mu\text{g L}^{-1}$ were observed for the target analytes. PF values
48
49 higher than 15.6-fold were obtained for the extraction of Bet, Nalt and Nalm at the concentration
50
51 level of $100 \mu\text{g L}^{-1}$. According to Clarke's analysis of drugs and poisons³², the serum therapeutic
52
53 concentration range for Bet is 5 to $50 \mu\text{g L}^{-1}$. After a single oral dose of 100 mg to four subjects,
54
55
56
57
58
59
60

1
2
3 peak plasma concentrations of 10 to 60 (mean 40) $\mu\text{g L}^{-1}$ of naltrexone were attained in 1 to 2 h. The
4
5 peak plasma concentration of 24 healthy males administrated with Nal, aged between 19 and 46
6
7 years, were in the range of 12-110 $\mu\text{g L}^{-1}$. Consequently, the proposed method can be applied for
8
9 extraction and determination of low levels of Nalm, Nalt and Bet from biological fluids.
10
11

12 13 **Application of the proposed method for analysis of real samples**

14
15 In order to illustrate the performance of the consecutive on chip EME, the procedure was used
16
17 for extraction and determination of Bet, Nalt and Nalm in urine and plasma samples. The obtained
18
19 results are presented in Table 3. As it can be seen, model analytes were not found in the investigated
20
21 urine and plasma samples. Therefore, urine and plasma samples were spiked with 100 $\mu\text{g L}^{-1}$ of Bet,
22
23 Nalt and Nalm. The relative error for extraction and determination of the model analytes in urine and
24
25 plasma samples were less than 5.2%. According to literature, the mean recovery will be within 90 to
26
27 110% (or relative Error% between -10% to +10%)³³. Therefore, the results showed that this method
28
29 is applicable for the real samples. Fig. 4 shows the typical chromatograms of the extracted model
30
31 analytes from urine and plasma samples before and after spiking with 100 $\mu\text{g L}^{-1}$ of Bet, Nalt and
32
33 Nalm.
34
35
36
37
38

39 40 **Conclusions**

41
42 In the present paper, for the first time, a consecutive on the chip EME extraction device was
43
44 introduced for the analysis of trace amounts of Bet, Nalt and Nalm as model analytes from low
45
46 volumes of urine and plasma samples. The effect of various variables affects the extraction
47
48 efficiency of the on chip EME procedure were investigated and optimized. Making the extraction
49
50 possibility from low volumes of biological fluids, providing considerable sample cleanup and
51
52 acceptable LODs are the advantages that can be accounted for the proposed method. The results
53
54
55
56

1
2
3 indicated that the consecutive on chip EME may be a good alternative for drug analysis from
4
5 biological samples.
6
7

8 9 **References**

- 10
11 1. H. Ebrahimzadeh, Y. Yamini, F. Kamarei and S. Shariati, *Anal. Chim. Acta*, 2007, 594, 93-
12 100.
13
- 14
15 2. M. Rezaee, Y. Yamini, M. Moradi, A. Saleh, M. Faraji and M. H. Naeeni, *J. Supercrit.*
16
17 *Fluids*, 2010, 55, 161-168.
18
- 19
20 3. M. H. Naeeni, Y. Yamini and M. Rezaee, *J. Supercrit. Fluids*, 2011, 57, 219-226.
21
- 22
23 4. S. Seidi, Y. Yamini and M. Rezazadeh, *J. Chromatogr. B*, 2013, 913–914, 138-146.
24
- 25
26 5. H. Chen, Q. Fang, X.-F. Yin and Z.-L. Fang, *Lab Chip*, 2005, 5, 719-725.
27
- 28
29 6. A. Sarafraz-Yazdi and A. Amiri, *TrAC Trends Anal. Chem.*, 2010, 29, 1-14.
30
- 31
32 7. Y. Ke, W. Li, Y. Wang, X. Hao, R. Jiang, F. Zhu and G. Ouyang, *Microchem. J.*, 2014, 117,
33 187-193.
34
- 35
36 8. H. Ebrahimzadeh, Y. Yamini, A. Gholizade, A. Sedighi and S. Kasraee, *Anal. Chim. Acta*,
37 2008, 626, 193-199.
38
- 39
40 9. Y. Assadi, M. A. Farajzadeh and A. Bidari, in *Comprehensive Sampling and Sample*
41
42 *Preparation*, ed. J. Pawliszyn, Academic Press, Oxford, 2012, pp. 181-212.
43
- 44
45 10. Y.-H. Jian, Y. Hu, T. Wang, J.-L. Liu, C. Zhang and Y. Li, *Chin. J. Anal. Chem.*, 2010, 38,
46 62-66.
47
- 48
49 11. M.-I. Leong and S.-D. Huang, *J. Chromatogr. A*, 2009, 1216, 7645-7650.
50
- 51
52 12. M. R. Khalili Zanjani, Y. Yamini, S. Shariati and J. Å. Jönsson, *Anal. Chim. Acta*, 2007, 585,
53 286-293.
54
55
56
57
58
59
60

13. T. Honda, M. Miyazaki, Y. Yamaguchi, H. Nakamura and H. Maeda, *Lab Chip*, 2007, 7, 366-372.
14. S. Pedersen-Bjergaard and K. E. Rasmussen, *J. Chromatogr. A*, 2006, 1109, 183-190.
15. Y. A. Asl, Y. Yamini, M. Rezazadeh and S. Seidi, *Anal. Methods*, 2015, 7, 197-204.
16. Z.-X. Cai, Q. Fang, H.-W. Chen and Z.-L. Fang, *Anal. Chim. Acta*, 2006, 556, 151-156.
17. A. Berduque, J. O'Brien, J. Alderman and D. W. M. Arrigan, *Electrochem. Commun.*, 2008, 10, 20-24.
18. H. Shen and Q. Fang, *Talanta*, 2008, 77, 269-272.
19. N. Petersen, H. Jensen, S. Hansen, S. Foss, D. Snakenborg and S. Pedersen-Bjergaard, *Microfluid Nanofluidics*, 2010, 9, 881-888.
20. N. J. Petersen, J. S. Pedersen, N. N. Poulsen, H. Jensen, C. Skonberg, S. H. Hansen and S. Pedersen-Bjergaard, *Analyst*, 2012, 137, 3321-3327.
21. S. Seidi, M. Rezazadeh, Y. Yamini, N. Zamani and S. Esmaili, *Analyst*, 2014, 139, 5531-5537.
22. B. Li, N. J. Petersen, M. D. R. Payán, S. H. Hansen and S. Pedersen-Bjergaard, *Talanta*, 2014, 120, 224-229.
23. M. D. Ramos Payán, H. Jensen, N. J. Petersen, S. H. Hansen and S. Pedersen-Bjergaard, *Anal. Chim. Acta*, 2012, 735, 46-53.
24. S. Seidi, Y. Yamini and M. Rezazadeh, *J. Pharm. Biomed. Anal.*, 2011, 56, 859-866.
25. L. Arjomandi-Behzad, Y. Yamini and M. Rezazadeh, *Anal. Biochem.*, 2013, 438, 136-143.
26. M. Rezazadeh, Y. Yamini and S. Seidi, *J. Chromatogr. B*, 2011, 879, 1143-1148.
27. M. Ghambarian, Y. Yamini and A. Esrafil, *J. Chromatogr. A*, 2012, 1222, 5-12.

- 1
2
3 28. T. M. Middelthon-Bruer, A. Gjelstad, K. E. Rasmussen and S. Pedersen-Bjergaard, *J. Sep.*
4
5 *Sci.*, 2008, 31, 753-759.
6
7
8 29. Y. Yamini, S. Seidi and M. Rezazadeh, *Anal. Chim. Acta*, 2014, 814, 1-22.
9
10 30. M. Rezazadeh, Y. Yamini and S. Seidi, *J. Sep. Sci.*, 2012, 35, 571-579.
11
12 31. A. Gjelstad, K. E. Rasmussen and S. Pedersen-Bjergaard, *J. Chromatogr. A*, 2007, 1174,
13 104-111.
14
15
16
17 32. A. C. Moffat, M. D. Osselton and B. Widdop, *Clarke's analysis of drugs and poisons*,
18 Pharmaceutical press London, 2011.
19
20
21
22 33. G. A. Shabir, *JVT*, 2005, 10, 314-325.
23
24
25
26 34. Guidance for Industry; Bioanalytical Method Validation, U.S. Department of Health and
27 Human Services, Food and Drug Administration, Rockville, 2001.
28
29
30
31
32
33
34

35 **Figures captions**

36
37
38 **Fig. 1.** Schematic illustration of consecutive on chip EME extraction cell with two extraction
39 chambers.
40

41
42 **Fig. 2.** Schematic illustration of consecutive on chip EME procedure.
43

44
45 **Fig. 3.** Optimization of (A) SLM composition, (B) applied voltage, (C) sample solution flow rate
46 and extraction time for Bet, Nalt and Nalm using consecutive on chip EME.
47
48

49
50 **Fig. 4.** Typical HPLC chromatograms obtained using consecutive on chip EME procedure for (A) a
51 urine sample and (B) a plasma sample after (a) and before (b) spiked with Bet, Nalt and Nalm at a
52 concentration level of $100 \mu\text{g L}^{-1}$.
53
54
55
56

Table 1Chemical structures, pK_a and $\log P$ of the model analytes.




Name	Chemical structure	pK_a	$\log P$
Betaxolol		9.67	2.54
Naltrexone		8.88	1.36
Nalmefene		9.57	1.95
Ref. [34]			

Table 2

Figures of merit of consecutive on chip EME for extraction of Bet, Nalt and Nalm.

Sample	Analytes	LOD ($\mu\text{g L}^{-1}$)	LOQ ($\mu\text{g L}^{-1}$)	Linearity ($\mu\text{g L}^{-1}$)	R ²	PF ^a	RSD% ^b
Urine	Bet	3.0	10.0	10.0-500	0.9958	17.1	4.2
	Nalt	3.0	10.0	10.0-500	0.9997	18.9	5.4
	Nalm	2.0	5.0	10.0-500	0.9991	19.5	4.8
Plasma	Bet	5.0	10.0	10.0-500	0.9932	15.6	5.4
	Nalt	5.0	10.0	10.0-500	0.9974	17.5	5.6
	Nalm	3.0	10.0	10.0-500	0.9942	18.9	6.8

^aPreconcentration factor at 100 $\mu\text{g L}^{-1}$.^bBased on four-replicate measurements.

Table 3

Determination of Bet, Nalt and Nalm in real samples using consecutive on chip EME.

Sample	Analyte	C_{real} ($\mu\text{g L}^{-1}$)	C_{added} ($\mu\text{g L}^{-1}$)	C_{found} ($\mu\text{g L}^{-1}$)	RSD% (n=4)	Error%
Urine	Bet	nd ^a	100.0	96.8	4.6	-3.2
	Nalt	nd	100.0	96.1	5.1	-3.9
	Nalm	nd	100.0	103.9	4.9	+3.9
Plasma	Bet	nd	100.0	95.1	5.3	-4.9
	Nalt	nd	100.0	94.8	6.2	-5.2
	Nalm	nd	100.0	104.2	5.1	+4.2

^aNot detected

Fig. 1




Fig. 2




Fig. 3




Fig. 4

